Tris Pharma picks up a $16.6 million NIAID grant, Penn receives a $19 million grant from the NIH, and Bristol Myers Squibb awarded $1 million to Drexel’s Biomed Engineering Program. For these and other life science stories, continue reading.
Weekly Quick Hits (Research Triangle Park) – Week of August 21, 2023 Animal health company Zoetis opened a new facility in Durham that is expected to help the company meet [….]
Weekly Quick Hits (Philly) – Week of August 21, 2023 Geneos reports positive early clinical trial results in liver cancer, FORE Biotherapeutics announces Matthew Ros will step down as CEO, [….]
Weekly Quick Hits (BHCR) – Week of August 21, 2023 FDA approves RSV vaccine for pregnant mothers, Adial regains Nasdaq listing, and Jane Carlton joins Johns Hopkins Malaria Research Institute. [….]
Johns Hopkins Wilmer Eye Institute Receives $20 Million Donation from T. Boone Pickens Foundation Additional funding from the T. Boone Pickens Foundation will create additional Professorships for young researchers at [….]
As Maryland seeks to become a hub for medical device scale-up, two local industry leaders share advice on partnership and support.
MyMD Pharmaceuticals advances its oral TNF-α inhibitor MYMD-1 into a Phase II study in patients with active rheumatoid arthritis. Non-profit pharma company Caring Cross, a Virginia Tech spinout, is featured in a paper on affordable and accessible gene therapies. Also in Virginia, CvilleBioHub secures an innovation grant from the Virginia Innovation Partnership Corporation.
Johns Hopkins’ Wilmer Eye Institute receives $20 million from The T. Boone Pickens Foundation, Emergent cuts jobs and programs to save $100 million per year, and more.
While the economy has slowed momentum for a number of RTP-based life sciences organizations, including a few bankruptcy filings earlier this summer, several companies are eying near-term growth, including Chiesi and Clinetic. Milestone Pharmaceuticals is also on the cusp of new growth, which could follow a planned Q3 NDA for its experimental PSVT treatment.
FDA approves Janssen’s Talvey for r/r Multiple Myeloma, Bristol Myers Squibb buys back $4 billion in shares, and plenty of Q2 reports. Read on for more news.